Literature DB >> 35976464

Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.

Fulvio Borella1, Stefano Cosma2, Domenico Ferraioli3, Isabelle Ray-Coquard3, Nicolas Chopin3, Pierre Meeus3, Vincent Cockenpot3, Giorgio Valabrega4, Giulia Scotto4, Margherita Turinetto4, Nicoletta Biglia5, Luca Fuso5, Luca Mariani5, Dorella Franchi6, Ailyn Mariela Vidal Urbinati6, Ida Pino6, Gianluca Bertschy2, Mario Preti2, Chiara Benedetto2, Isabella Castellano7, Paola Cassoni7, Luca Bertero7.   

Abstract

BACKGROUND: The term uterine smooth muscle tumor of uncertain malignant potential (STUMP) indicates a rare, equivocal entity between benign leiomyomas and leiomyosarcomas. In the present study, we evaluated a comprehensive range of clinical, surgical, and pathological features in a large multicenter series of patients with STUMP to identify risk factors for recurrence.
METHODS: This is a retrospective study performed by collecting consecutive cases diagnosed between January 2000 and December 2020 in five tertiary centers. Associations between STUMP recurrence and clinicopathological characteristics as well as surgical treatment modality were investigated.
RESULTS: Eighty-seven patients affected by STUMP were considered. Of them, 18 cases (20.7%) recurred: 11 as leiomyosarcoma (LMS) and 7 as STUMP. The mean time to recurrence was 79 months. We found that fragmentation/morcellation, epithelioid features, high mitotic count, Ki-67 value > 20%, progesterone receptor (PR) < 83%, and p16 diffuse expression were associated with higher risk of recurrence and shorter recurrence-free survival (RFS). Furthermore, morcellation/fragmentation and mitotic count remained independent risk factors for recurrence and shorter RFS after multivariate analysis, while the presence of epithelioid features was an independent risk factor for recurrence only.
CONCLUSIONS: Our results suggest that morcellation is associated with risk of recurrence and shorter RFS, thus it should be avoided if a STUMP is suspected preoperatively. Epithelioid features, high proliferation activity, low PR expression, and diffuse p16 expression are also unfavorable prognostic factors, so patients presenting these features should be closely followed up.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35976464     DOI: 10.1245/s10434-022-12353-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


  38 in total

1.  A clinicopathologic study of uterine smooth muscle tumours of uncertain malignant potential (STUMP).

Authors:  Joseph S Y Ng; Aaron Han; Sung Hock Chew; Jeffrey Low
Journal:  Ann Acad Med Singapore       Date:  2010-08       Impact factor: 2.473

2.  The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.

Authors:  Derman Basaran; Alp Usubutun; Mehmet Coskun Salman; Mehmet Ali Narin; Gokhan Boyraz; Osman Turkmen; Gunsu Comert Kimyon; Alper Karalok; Dilek Bulbul; Taner Turan; Nejat Ozgul; Kunter Yuce
Journal:  Int J Gynecol Cancer       Date:  2018-02       Impact factor: 3.437

3.  Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters.

Authors:  Mamta Gupta; Anna L Laury; Marisa R Nucci; Bradley J Quade
Journal:  Histopathology       Date:  2018-05-21       Impact factor: 5.087

4.  Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.

Authors:  Andrea Dall'Asta; Salvatore Gizzo; Andrea Musarò; Michela Quaranta; Marco Noventa; Costanza Migliavacca; Giulio Sozzi; Michela Monica; Daniele Mautone; Roberto Berretta
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 5.  [Smooth muscle tumor of uncertain malignant potential (STUMP)--clinico-pathomorphological analysis of the cases and literature review].

Authors:  Anna Dańska-Bidzińska; Elwira Bakuła-Zalewska; Anna Nasierowska-Guttmejer; Magdalena Kowalewska; Edyta Barnaś; Piotr Sobiczewski; Mariusz Bidziński
Journal:  Ginekol Pol       Date:  2012-06       Impact factor: 1.232

6.  Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.

Authors:  Saketh R Guntupalli; Pedro T Ramirez; Matthew L Anderson; Michael R Milam; Diane C Bodurka; Anais Malpica
Journal:  Gynecol Oncol       Date:  2009-04-02       Impact factor: 5.482

7.  Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.

Authors:  Philip P C Ip; Annie N Y Cheung; Philip B Clement
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

8.  Uterine Smooth Muscle Tumor of Uncertain Malignant Potential: Clinicopathologic-Sonographic Characteristics, Follow-Up and Recurrence.

Authors:  Besim Haluk Bacanakgil; Mustafa Deveci; Emine Karabuk; Zeynep Soyman
Journal:  World J Oncol       Date:  2017-06-09

9.  Oncologic and Reproductive Outcomes of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential: A Single Center Retrospective Study of 67 Cases.

Authors:  Lanqing Huo; Dan Wang; Wenze Wang; Dongyan Cao; Jiaxin Yang; Ming Wu; Junjun Yang; Yang Xiang
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

10.  Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes.

Authors:  Hanifi Şahin; Funda Karatas; Gonca Coban; Özlem Özen; Özlem Erdem; Mehmet Anıl Onan; Ali Ayhan
Journal:  J Gynecol Oncol       Date:  2019-02-04       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.